KRAZATI
Generic: adagrasib
- Manufacturer
- Mirati
- NDC
- 80739-812
- RxCUI
- 2625917
- Route
- ORAL
- ICD-10 indication
- C34.90
Affordability Check
How much will you actually pay for KRAZATI?
In 30 seconds, see every legitimate way to afford KRAZATI — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About KRAZATI
What is this medication? Krazati is a prescription medicine used to treat adults with a specific type of lung cancer called non-small cell lung cancer. It is specifically intended for patients whose cancer has spread to other parts of the body or cannot be removed by surgery and possesses an abnormal KRAS G12C gene. This medication is typically prescribed after a patient has already received at least one other form of systemic cancer treatment that did not work or has stopped working.
This medication belongs to a class of drugs known as RAS GTPase inhibitors. It works by blocking the activity of the mutated KRAS G12C protein, which helps to slow down or stop the growth and spread of cancer cells. Krazati is taken orally in the form of tablets, usually twice daily, and requires a specific diagnostic test to confirm the presence of the genetic mutation before treatment begins.
Copay & patient assistance
- Patient Copay Amount: Eligible patients may pay as little as $0 per monthly supply or per infusion/dose for most select BMS medications; for Nulojix (Kidney Transplant), eligible patients may pay as little as $50 per outpatient dose.
- Maximum Annual Benefit Limit: Not Publicly Available (The program is subject to a maximum benefit, but specific dollar amounts are not listed in the provided text).
- Core Eligibility Restrictions: Patients must have commercial (private) insurance; patients are ineligible if they have government-funded insurance including Medicare, Medicaid, or TRICARE; must be a U.S. resident.
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for adagrasib.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup KRAZATI →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for adagrasib →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Medicare Part D coverage
How KRAZATI appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).
Covered by plans
57%
3,112 of 5,499 plans
Most common tier
Tier 5
On 79% of covering formularies
Prior authorization required
99%
of covering formularies
| Tier | Formularies on this tier | Share |
|---|---|---|
| Tier 1 (preferred generic) | 59 | 18% |
| Tier 2 (generic) | 2 | 1% |
| Tier 4 (non-preferred brand) | 7 | 2% |
| Tier 5 (specialty) | 259 | 79% |
| Tier 6 | 1 | 0% |
Step therapy: 0% of formularies
Quantity limits: 87% of formularies
Coverage breadth: 328 of 65 formularies
How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
EVEROLIMUS
Treats same condition · Everolimus
AVMAPKI FAKZYNJA CO-PACK
Treats same condition · avutometinib potassium and defactinib hydrochloride
Fludeoxyglucose F18
Treats same condition · Fludeoxyglucose F18
Portrazza
Treats same condition · necitumumab
Pilocarpine Hydrochloride
Treats same condition · Pilocarpine Hydrochloride
TEPADINA
Treats same condition · THIOTEPA
AVGEMSI
Treats same condition · Gemcitabine
CLENPIQ
Treats same condition · SODIUM PICOSULFATE, MAGNESIUM OXIDE, and ANHYDROUS CITRIC ACID
Niva Thyroid
Treats same condition · thyroid, porcine
Kisunla
Treats same condition · donanemab-azbt
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.